TG Therapeutics, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference
Jan 09, 2017 12:31 pm UTC| Business
NEW YORK, Jan. 09, 2017 -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare...
TG Therapeutics, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference
Jan 09, 2017 12:31 pm UTC| Business
NEW YORK, Jan. 09, 2017 -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare...
Ollie’s Bargain Outlet Holdings, Inc. Reports Strong Holiday Sales and Raises Full Year Outlook
Jan 09, 2017 12:30 pm UTC| Business
HARRISBURG, Pa., Jan. 09, 2017 -- Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) (“Ollie’s” or the “Company”) today commented on its holiday sales and full year outlook ahead of its participation at the 2017 ICR...
Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance
Jan 09, 2017 12:30 pm UTC| Business
Strong Momentum for Galafold Launch in Europe and Multiple Global Regulatory Submissions Ahead Additional Data from Pompe Phase 1/2 Clinical Study and Top-Line Data from Phase 3 Epidermolysis Bullosa Study Expected in...
Strongbridge Biopharma plc Expands Commercial Capabilities with Two Rare Disease Executive Hires
Jan 09, 2017 12:30 pm UTC| Business
DUBLIN, Ireland and TREVOSE, Pa., Jan. 09, 2017 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare...
Jan 09, 2017 12:30 pm UTC| Business
MENLO PARK, Calif., Jan. 09, 2017 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced a new version of chemistry (V2) and software (V4) for the Sequel™ System. The new release improves the system’s...
Jan 09, 2017 12:30 pm UTC| Business
-- Company Initiates Phase III “ADVOCATE” Clinical Trial for Complement Receptor Inhibitor Avacopan in ANCA Vasculitis; Development Path Outlined in Rare Kidney Disease for Chemokine Receptor Inhibitor ‘CCX140’ -- ...